Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

BACKGROUND: Heart failure (HF) patients with atrial fibrillation (AF) often have conduction system disorders, which may be worsened by β-blocker therapy. OBJECTIVE: In a post hoc analysis we examined the prevalence of bradycardia and its association with adverse events (AEs) and failure to achieve t...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, William T., Piccini, Jonathan P., Dufton, Christopher, Carroll, Ian A., Healey, Jeffrey S., O’Connor, Christopher M., Marshall, Debra, Aleong, Ryan, van Veldhuisen, Dirk J., Rienstra, Michiel, Wilton, Stephen B., White, Michel, Sauer, William H., Anand, Inder S., Huebler, Sophia P., Connolly, Stuart J., Bristow, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859785/
https://www.ncbi.nlm.nih.gov/pubmed/35243434
http://dx.doi.org/10.1016/j.hroo.2021.11.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859785/
https://www.ncbi.nlm.nih.gov/pubmed/35243434
http://dx.doi.org/10.1016/j.hroo.2021.11.005

Ejemplares similares